Trial
NCT01576549
A Study of LY2127399 in Rheumatoid Arthritis
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Rheumatoid Arthritis
Intervention
LY2127399
Why stopped
Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-26